Skip to main content
Medical information Clinical review pending

Genetic Testing

ACTN2 Gene Cardiomyopathy Dilated Type 1AA Genetic Test

This genetic test analyzes the ACTN2 gene to identify potential risks for Dilated Cardiomyopathy Type 1AA. It uses Next-Generation Sequencing (NGS) technology to detect gene mutations linked to this heart condition.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or Saliva sample (collection kit provided). Confirm with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the ACTN2 Gene Cardiomyopathy Dilated Type 1AA Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with symptoms suggestive of cardiomyopathy (e.g., shortness of breath, fatigue, irregular heartbeat).
  • ✓Individuals with a family history of cardiomyopathy or sudden cardiac death.
  • ✓Patients diagnosed with heart conditions seeking genetic risk assessment.
  • ✓Family members of individuals diagnosed with ACTN2-related cardiomyopathy.
02

In plain language

What this test helps you understand

Identifies genetic mutations in the ACTN2 gene associated with Dilated Cardiomyopathy Type 1AA, aiding in risk assessment and family planning.
The ACTN2 Gene Cardiomyopathy Dilated Type 1AA NGS Genetic DNA Test is a diagnostic tool used to identify genetic predispositions to a specific type of cardiomyopathy. This condition affects the heart muscle, making it difficult for the heart to pump blood effectively. Understanding your genetic risk can be crucial for managing heart health.

This test focuses on the ACTN2 gene, which plays a role in the structure and function of heart muscle cells. By examining this gene, the test can detect variations or mutations that are associated with Dilated Cardiomyopathy Type 1AA. We utilize advanced Next-Generation Sequencing (NGS) technology for accurate analysis.

This test is particularly relevant for individuals with a family history of heart disease or cardiomyopathy, or those experiencing symptoms related to heart function. Early identification of genetic risks can inform preventative measures and treatment strategies.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube) or Saliva sample (collection kit provided). Confirm with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) of the ACTN2 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the ACTN2 gene. It does not detect mutations in other genes associated with cardiomyopathy. A negative result does not completely rule out a genetic predisposition to heart disease. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This is a specific type of cardiomyopathy, a condition where the heart muscle becomes weakened and enlarged, affecting its ability to pump blood. Type 1AA is linked to mutations in the ACTN2 gene.
This test is recommended for individuals experiencing symptoms of cardiomyopathy, those with a family history of the condition, or those diagnosed with heart disease seeking genetic insights.
The ACTN2 gene provides instructions for making a protein important for the structure and function of muscle cells, including the heart muscle.
The test uses Next-Generation Sequencing (NGS), a highly accurate method for detecting genetic variations. However, it only analyzes the ACTN2 gene.
It is recommended to discuss your results with a healthcare provider or genetic counselor to understand their meaning and any potential implications for your health or family.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp